Result of Meeting

RNS Number : 6752C

Advanced Oncotherapy PLC

23 January 2018

 

23 January 2018

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Result of GM

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today, all resolutions were duly passed.

For further information contact:

Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, Executive Chairman Tel: [phone] Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi / Ed Thomas Tel: [phone] Stifel Nicolaus Europe (Joint Broker) Jonathan Senior / Ben Maddison Tel: [phone] Walbrook PR (Financial PR & IR) Tel: [phone] or [e-mail] Paul McManus / Anna Dunphy Mob: [phone] / Mob: [phone]

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM", based in Geneva, focuses on the development of a proprietary proton accelerator called Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control which is not achievable with older technologies.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with an innovative technology as well as lower treatment related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

END

 

 

ROMDMGZMMFNGRZM